Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China - Scorecard - MDSpire
Advertisement
Clinical Characteristics, Autoantibody Profiles, and Therapeutic Outcomes of Juvenile Systemic Sclerosis: An 11-Year Single-Center Experience from China
Clinical Scorecard: Clinical Features, Autoantibody Profiles, and Treatment Outcomes in Pediatric Systemic Sclerosis: Insights from an 11-Year Study at a Chinese Center
At a Glance
Category
Detail
Condition
Juvenile Systemic Sclerosis (jSSc)
Key Mechanisms
Multiorgan involvement with distinct autoantibody profiles
Target Population
Pediatric patients with jSSc
Care Setting
Retrospective analysis at a Chinese medical center
Key Highlights
Skin sclerosis was the predominant symptom in all patients (100%)
ANA positivity was observed in 76.2% of patients
Significant reduction in overall disease severity (J4s) and skin involvement (mRSS) after treatment
Biologic therapies, including tocilizumab, were utilized in 14 patients
No fatalities or severe adverse events reported during follow-up
Guideline-Based Recommendations
Diagnosis
Classification according to 2013 ACR/EULAR systemic sclerosis criteria
Management
Initial treatment with glucocorticoids and methotrexate; consider biologics like tocilizumab
Monitoring & Follow-up
Utilize J4s and mRSS for assessing disease severity and treatment response
Risks
Monitor for potential adverse events, though none reported in this study
Patient & Prescribing Data
21 pediatric patients with jSSc
Median treatment duration of 24 months showed significant clinical improvement
Clinical Best Practices
Timely diagnosis of jSSc is crucial for better outcomes
Personalized treatment strategies should be employed
Regular monitoring using objective assessment tools is recommended
